Physician profile
Allen Redding
NPI 1538197256
$6,655.28
in general payments reported to CMS, 2019-2025
39 companies · $1,825 in 2025
The $1,825 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $277 · 2021: $90.71 · 2022: $422 · 2023: $1,421 · 2024: $2,121 · 2025: $1,825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,366.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $605.37 | 2020-2025 | Mounjaro, Jardiance, Trulicity |
| Dexcom, INC. | $605.16 | 2019-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $563.27 | 2022-2025 | |
| Amgen INC. | $531.97 | 2019-2025 | Evenity, Prolia, Tepezza |
| Abbvie INC. | $519.35 | 2019-2025 | |
| Corcept Therapeutics | $365.15 | 2023-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $364.01 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Abbott Laboratories | $363.44 | 2020-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $306.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $246.00 | 2020-2025 | |
| Cequr Corporation | $226.16 | 2024-2025 | Cequr Simplicity |
| Mannkind Corporation | $162.26 | 2023-2024 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.98 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $148.84 | 2022-2025 | |
| Insulet Corporation | $148.21 | 2021-2025 | Omnipod |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $113.74 | 2022-2024 | Tymlos |
| Kyowa Kirin, INC. | $106.34 | 2023-2024 | Crysvita |
| Ascendis Pharma Endocrinology INC | $98.60 | 2023-2025 | Yorvipath, Skytrofa |
| Neurocrine Biosciences, INC. | $97.06 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $95.80 | 2023-2025 | Isturisa, Signifor Lar |
| Antares Pharma, INC. | $76.81 | 2024 | Xyosted |
| Regeneron Healthcare Solutions, INC. | $73.42 | 2019-2025 | Evkeeza |
| Almatica Pharma LLC | $72.68 | 2024-2025 | Teriparatide |
| Tandem Diabetes Care, INC. | $69.28 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $66.21 | 2019-2020 | |
| Beta Bionics, INC. | $65.91 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Chiesi USA, INC. | $61.04 | 2024-2025 | Mycapssa |
| Nevro Corp. | $57.96 | 2023-2024 | Senza |
| Averitas Pharma INC. | $54.22 | 2024-2025 | Qutenza |
| Boston Scientific Corporation | $40.62 | 2020 | |
| Sequel Med Tech, LLC | $36.98 | 2025 | Twiist |
| Medtronic, INC. | $23.03 | 2024 | Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $22.67 | 2023 | Steglatro, Steglujan |
| Ascensia Diabetes Care US INC. | $21.57 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $20.20 | 2025 | Imcivree |
| Halozyme INC | $19.66 | 2023 | |
| Soleno Therapeutics, INC. | $18.73 | 2025 | Vykat Xr |
| Globus Medical, INC. | $15.16 | 2025 | Senza |
| Amarin Pharma, INC. | $13.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Redding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.